Immunome Inc. (IMNM) saw its stock price plummet by 5.08% in Friday's trading session following the release of its full-year 2024 financial results. The biotechnology company reported a significant widening of its net loss and missed analyst expectations, raising concerns among investors about its financial performance and future prospects.
The company reported a net loss of $293.0 million for the full year 2024, representing a substantial 174% increase from the previous year. This translated to a loss of $5.00 per share, which was 14% worse than analyst estimates. Additionally, Immunome's revenue fell short of expectations, missing analyst forecasts by 3.9%.
Despite the disappointing results, analysts remain cautiously optimistic about Immunome's long-term potential. Revenue is forecast to grow at an average rate of 53% per annum over the next three years, outpacing the 20% growth projected for the US Biotechs industry. However, investors will be closely monitoring the company's ability to narrow its losses and achieve its growth targets in the coming quarters.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。